タイトル:

出版社:

ISBN:

著者:

キーワード:

カテゴリー:

発行年:

～

検索条件をクリア

書籍詳細

未契約

書籍名	腎移植における免疫抑制療法
出版社	日本医学館
発行日	1998-01-22
著者	高橋公太(編集)
ISBN	489044369x
ページ数	289
版刷巻号	第1版第1刷
分野	臨床医学：外科移植/人工臓器
閲覧制限	未契約

本書には現在臨床の場で使用されている種々の免疫抑制剤の効力発揮のメカニズム、薬物動態をはじめ、腎移植臨床における維持免疫抑制剤としての投与方法が具体的に述べられており、また拒絶反応が起こったときの薬剤による治療方法の詳細が理解しやすく記述されている。

目次

表紙
閲覧
執筆者一覧
閲覧
本書の刊行に寄せて
閲覧
序
閲覧
目次
閲覧
総論
P.1閲覧
- 1. 免疫抑制剤とそのメカニズム
- 2. 免疫抑制剤の薬物動態
投与法
P.39閲覧
- 維持免疫抑制剤
- 拒絶反応治療薬
- 慢性拒絶反応の予防と治療
- 血漿交換療法
索引
P.273閲覧
奥付
閲覧

参考文献

総論

P.17 掲載の参考文献

1) 落合武徳:腎, 肝, 膵, 心移植の現況. 千葉医学 56:235-242, 1980.

2) 落合武徳, 浅野武秀, 磯野可一:臓器移植のバイオエシックス. 千葉医学 62:179-186, 1986.

3) Cecka JM, Terasaki PI:The UNOS Scientific Renal Transplant Registry. Clinical Transplants 1995. (ed. Terasaki PI) , UCLA Tissue Typing Laboratory, Los Angeles, 1996, p1-16.

4) Murray JE:The first successful transplantation in man. History of Transplantation. (ed. Terasaki PI) , UCLA Tissue Typing Laboratory, Los Angeles, 1991, p 121-143.

5) Calne RY, Murray JE:Inhibition of the rejection of renal homografts in dogs. Surg. Forum 12:118, 1961.
pubmed

6) Goodwin WE, Kaufman JJ, Mins MM:Human renal transplantation. J. Urol. 89:13-24, 1963.

7) 岩崎洋治, 高橋英世, 小高道夫, 大川治夫, 雨宮浩・他:同所性同種肝移植の臨床への応用. 外科 31:1383-1389, 1969.

8) 岩崎洋治, 横山健郎, 雨宮浩, 小高通夫, 落合武徳:死体腎移植術. 移植 4:79-84, 1969.

9) 有田誠司, 浅野武秀, 榎本和夫, 永田松夫, 後藤剛貞・他:皮膚癌にて失った死体腎移植18年生着症例. 日本外科学会雑誌 89:1726-1729, 1988.

10) Iwasaki Y, Porter KA, Starzl TE:The preparation and testing of horse antidog and antihuman antilymphoid plasma or serum and its protein fractions. Surg. Gynec. Obstet. 124:1-24, 1967.
pubmed

11) Starzl TE, Porter KA:Antilymphocyte globulins. Human Transplantation. (eds, apaport FT, Dausset J) , Grune & Stratton, New York, 1968, p 489-498.

12) 深尾立, 落合武徳, 岩崎洋治, 佐藤博:ウマ抗ヒトリンパ球血清の作製方法ならびに精製方法. 移植 6:68-77, 1971.

13) 雨宮浩, 落合武徳, 深尾立, 岩崎洋治, 佐藤博:抗リンパ球血清の臨床効果. 臨床免疫 8:873-879, 1976.

14) 落合武徳, 浅野武秀, 佐藤博, 柏木登, 雨宮浩:抗リンパ球血清の多施設におけるControlled Studyの臨床結果. 移植 17:391-400, 1982.
Medical*Online

15) Ochiai T, Ahmed A, Strong DM:Specificity and immunosuppressive potency of a rabbit anti-mouse T cell specific antiserum. Transplantation 20:198-210, 1975.

16) Cosimi AB, Burton RC, Colvin RB:Treatment of acute renal allograft rejection with OKT 3 monoclonal antibody. Transplantation 32:535-539, 1981.

17) Cecka M, Cicciarelli J:The transfusion effect. Clinical Kidney Transplant 1985. (ed. Terasaki PI) , UCLA Tissue Typing Laboratory, Los Angeles, 1985, p 73-92.

18) Ochiai T, Gunji Y, Nagata M, Isono K:Cyclosporine enhances an effect of donor-specific blood transfusion in canine renal transplantation. Transplant. Proc. 15:2939-2941, 1983.

19) Borel JF, Feurer C, Magnee C, Stahelin II:Effects of the new anti-lymphocytic peptide cyclosporin A in animals. Immunology 32:1017-1025, 1977

20) Borel JF, Baumann G, Chapman I:In vivo pharmacological effects of ciclosporin and some analogues. Advances in Pharmacology 35:115-246, 1996.
pubmed

21) Calne RY, White DJG, Rolles K:Prolonged survival of pig orthotopic heart grafts treated with cyclosporin A. Lancet 1:1183-1185, 1978.

22) Calne RY, White DJG, Thiru S:Cyclosporin A in patients receiving renal allografts from cadaver donors. Lancet 2:1323-1327, 1978.

23) Starzl TE, Iwatsuki S, Shaw BW, Gordon RD:Liver transplantation in the Ciclosporin Era. Prog, Allergy 38:366-394, 1986.
pubmed

24) 落合武徳, 東間紘, 高木弘, 岡隆宏:腎移植におけるCiclosporinの多施設協同研究報告. 移植 21:255-278, 1986.
Medical*Online

25) 奥原正国:免疫抑制剤 FK 506の発見. 現代化学 1996年10月号:22-28, 1996.

26) Ochiai T, Nagata K, Nakajima M, Isono K:Studies on the effects of FK 506on the renal allografting in the beagle dog. Transplantation 44:723-733, 1987.

27) Ochiai T, Nakajima K, Nagata M, Isono K:Studies on the induction and maintenance of long-term graft acceptance by treatment of FK 506in heterotopic cardiac allotransplantation of rats. Transplantation 44:734-738, 1987.

28) Inamura N, Nakahara K, Kino T, Ochiai T:Prolongation of skin allograft survivalin rats by a novel immunosuppressive agents, FK 506. Transplantation 45:206-209, 1988.

29) Ochiai T, Gunj i Y, Sakamoto K, Isono K:Optimal serum trough levels of FK 506in renal allotransplantation of the beagle dog. Transplantation 48:189-193, 1989.

30) Starzl TE, Todo S, Fung J:FK 506for liver, kidney and pancreas transplantation. Lancet 2:1000-1004, 1989.
pubmed

31) Inomoto T, Nishizawa F, Sasaki H, Tanaka K, Yamaoka Y:Experience of 120 microsurgical reconstructions of hepatic artery in living related liver transplantation. Surgery 119:20-26, 1996.

32) Schwarz RS:Immunosuppressive drug therapy. Human Transplantation. (eds. Rapaport FT, Dausset J) , Grurle & Stratton, New York, 1968, p 440-471.

33) 稲生綱政:腎移植におけるBredininの免疫抑制効果. 移植 17(suppl.):547-561, 1982.
Medical*Online

34) 雨宮浩:腎移植後の拒絶反応に対する治療効果. デオキシスパガリン. (雨宮浩編), 日本医学館, 東京, 1994, p77-95.

35) Eugui EM, AlmQuist SJ, Muller CM, Alloson AC:Lymphocyte-selective cytostatic and immunosuppressive effects of mycophenolic acid in vitro. Scand. J. Immunol. 33:161-174, 1991.

36) Sollinger HW, US Renal Transplant Mycophenolate Mofetil Study Group:Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. Transplantation 60:225-232, 1995.

37) European Mycophenolate Mofetile Cooperative Study Group:Placebo-controlled study of mycophenolate mofetil combined with cyclosporine and corticosteroids for prevention of acute rejection. Lancet 345:1321-1325, 1995.

38) Takahashi K, Ochiai T, Uchida K:Pilot study of Mycophenolate mofetilin the prevention of acute rejection in Japanese patients. Transplant. Proc. 27:1421-1424, 1995.

39) 早坂勇太郎:作用機序. 新しい免疫抑制剤. (太田和夫, 高橋公太編), 医歯薬出版, 東京, 1991, p8-24.

40) 太田和夫, 園田孝夫, 高木弘:腎移植後の急性拒絶反応に対するmuromonab CD3の治療効果. 腎と透析 24:143-156, 1989.

41) Amlot PL, Rawlings E, Fernando ON:Prolonged action of a chimeric CD 25 monoclonal antibody used in cadaveric renal transplantation. Transplantation 60:748 756, 1995.

42) Schreiber SL:Chemistry and biology of the immuophilins and their immunosuppressive ligands. Science 251:283-287, 1991.
pubmed

43) Schreiber SL, Crabtree GR:The mechanismus of action of cyclosporin A and FK 506. Immunology Today 13:136142, 1992.

44) 軍司祥雄, 落合武徳, 磯野可一:免疫抑制剤. 移植と免疫. (猪子英俊編), 中外医学社, 東京, 1993, p132-151.

45) 高橋信弘:免疫抑制剤による免疫抑制. 移植免疫学. (藤原大美編), 中外医学社, 東京, 1992, p113-137.

46) Wang T, Donahoe PK, Zervos AS:Specific interaction of type I receptors of the TGFβ family with the immunophilin FKBP 12. Science 265:674-676, 1994.

47) Ahuja S, Shrivastav S, Daielpour D, Balow J:Regulation of transforming growth factor-β and its receptor by cyclosporine in human T-lymphcytes. Transplantation 60:718-723, 1995.

48) Gjertson M, Cecka JM, Terasaki PI:The relative effects of FK 506and cyclosporine on short and long term kidney graft survival. Transplantation 60:1384-1388, 1995.

49) Jutila MA:Role of changes in the vascular endothelium in chronic inflammation. Clin. Transpl. 8:304-307, 1994.

50) Lemster BH, Carroll PB, Rilo HR:IL8/IL8 receptor expression in psoriasis and the response to systemic tacrolimus therapy. Clin. Exp. Immunol. 99:148-154, 1995.

51) Todo S, Fung JJ, Starzl TE:Single-center experience with primary orthotopic liver transplantation with FK 506immunosuppression. Ann. Surg. 220:297-309, 1994.
pubmed

52) The U. S. multicenter FK 506liver study group:A comparison of tacrolimus and cyclosporine for immunosuppression in liver transplantation. N. Engl. J. Med. 331:1110-1115, 1994.

53) Williams R, Neuhaus P, Bismuth H:Two-year data from the European multicenter tacrolimus liver study. Transpl. Int. 9 (suppl. 1):s144-s150, 1996
pubmed

54) Woodle ES, Thistlethwaite JR, Gordon JH, Laskow D, Deierhoi MH et al.:A multicenter trial of FK 506therapy in refractory acute renal allograft rejection. Trransplantation 62:594-599, 1996.

55) van Hooff J, The European Tacrolimus Multicenter Renal Study Group:The European multicenter prospective randomized trial comparing tacrolimus and cyclosporin in the prevention of renal allograft rejection. 16th International Congress of the Transplantation Society, Barcelona, 1996.

56) 落合武徳, 深尾立, 高橋公太, 大田和夫:腎移植におけるFK 506の第3相比較試験. 移植 29:650-681, 1994.

57) Porayko MK, Textor SC, Krom RAF, Hay JE:Nephrotoxic effects of primary immunosuppression with FK 506and cyclosporine regimens after liver transplantation. Mayo Clin. Proc. 69:105-111, 1994.

58) Ochiai T, Sakamoto K, Gunji Y, Isono K:Effects of combination treatment with FK 506and Cyclosporine on survival time and vascular changes in renal-allograft recipient dogs. Transplantation 48:193-197, 1989.

59) Mueller EA, Kovarik JM, van Bree JB, Lison AE:Safety and steady-state pharmacokinetics of a new oral formulation of cyclosporin A in renal transplant patients. Transplant. Int. 7 (suppl. 1):s 267-s 269, 1994.

60) Sehgal SN, Baker H, Vezina C:Rapamycin, a new antifubgal antibiotic. J. Antibiot. 28:727, 1975.
pubmed

61) Calne RY, Collier D St. J, Lim S:Rapamycin for immunosuppression for organ allografting. Lancet 2:227, 1989.

62) Morris RE:Rapamycins;antifungal, antitumor, antiproliferative and immunosuppressive macrolides. Transplantation Review 6:39-87, 1992.

63) Ochiai T, Gunji Y, Nagata M, Isono K:Effects of Rapamycin in experimental organ transplantation. Transplantation 56:15-19, 1993.
pubmed

64) Ochiai T, Gunji Y, Nagata M, Isono K:Effective and safe use of FK 506;Combination treatment with Rapamycin and RS-61443 in experimental organ transplantation. Transplant. Proc. 23:2718-2719, 1991.
pubmed

65) Nakajima K, Ochiai T, Nagata M, Isono K:Effect of triple therapy of cyclosporine, FK 506and RS-61443 on allogeneic small bowel transplantation in dogs. Transplant. Proc. 25:595-596, 1993.

66) Sakamoto K, Ochiai T, Sato H:Enforcement of specific unresponsiveness by the long-term graft acceptance in the rat. Transplantation 37:97-100, 1984.

67) Ochiai T, Nakagohri S, Isono K:Studies on FK 506in experimental organ transplantation. Transplant. Proc. 20 (suppl. 1):209-214, 1988.

68) Ochiai T, Hori S, Nakajima K, Isono K:Prolongation of rat heart allograft survival by 15-deoxyspergualin. J. Antibiot. 40:249-250, 1987.
pubmed

P.36 掲載の参考文献

1) 高原史郎, 小角幸人, 亀岡博, 石橋道男・他:Mizoribineを使用した多剤併用免疫抑制療法の臨床検討. 今日の移植 8:143-146, 1995.

2) Meteslaar HJ, Weimar W:Cytomegalovirus infection and renal transplantation. J. Antimicro. Chemother. 23:37-47, 1989.

3) Sjoqvist F, Borga O, Orme M:Fundamentals of clinical pharmacology. (ed. Avery. GS) , Drug Treatment. Prirlciples and Practice of clinical Pharmacology and Therapeutics (2nd ed.).

4) Lindholm A:Factors influencing the pharmacokinetics of cyclosporine in man. Ther. Drug. Monit. 13:465, 1991.
pubmed

5) Kolars JC, Awni WM, Merion RM et al.:First-pass metabolism of cyclosporin by thegut. Lancet 338:488-1490, 1991.

6) Kokado Y, Takahara S:Pharmacokinetics of mizoribine in renal transplant patients. Transplant. Proc. 26:111-2113, 1994.

7) Yee GC, McGuire TR:Pharmacokinetic drug interactions with cyclosporin. Clin. Pharmacokinetics 19:319-332, 1990.

8) Ben-Ari J, Eisenstein B, Davidovits M et al.:Clinical and laboratory observations:Effect of erythromycin on blood cyclosporine concentrations in kidney transplant patients. J. Pediatr. 112:992, 1988.

9) Chan GL, Sinnott JT, Emmanuel PJ et al.:Drug interactions with cyclosporine:Focus on antimicrobial agents. Clin. Transplantation 6:141, 1992.

10) 高原史郎:腎移植におけるシクロスポリン血中濃度の日内変動測定の意義. 今日の移植 5:59-65, 1992.

11) Vonderscher J, Meinzer:The neoral formula of cyclosporine. Transplant. Proc. 26:2925-2927, 1994.

12) Yoshimura N, Oka T:FK 506, a new immunosuppressive agent:a review. J. Immunol. Immunopharmacol. 10:32-36, 1990.

13) 高原史郎, 高野右嗣・他:腎移植におけるFK506血中濃度測定の意義. 日泌尿会誌 84:1857-1864, 1993.

14) 高原史郎, 林哲朗, 田辺一成, 大田和夫:高感度IMx法による血中タクロリムス濃度測定-その信頼性の評価-. 今日の移植 10:91-95, 1997.

15) Woocle ES et al.:A multicenter trial of FK 506(tacrolimus) rescue therapy in renal transplantation. Int. Conf. New. Trends. Clin. Exp. immunosuppr (2nd). Geneva, Switz.

16) Gierton DW et al.:The relative effects of FK 506and cyclosporine on short-and long-term kidney graft survival. Transplant. 60:1384-1388, 1995.

17) Japanese FK 506Study Group:Japanese study of kidney transplantation:1. Resultsof early phase II study. Transplant. Intern. 5 (Suppl. 1):524-528, 1992.

18) Japanese FK 506Study Group:Japanese study of kidney transplantation:2. Follow-up study of FK 506-treated patients. Transplant. Intern. 5 (Suppl. 1):552-555, 1992.

19) Hosotsubo H, Takahara S, Taenaka N:Simplified high-performance liquidchromatographic method for determination of mizoribine in human serum. J. Chromatogr. 42:340-345, 1988.

20) 細坪秀夫, 出口松夫, 和泉由紀子・他:全自動蛍光偏光免疫測定装置 (TDx アナライザー) を用いたモノクローナル抗体使用による全血シクロスポリン濃度測定の基礎検討. 臨床検査機器試薬 16:315-324, 1993.

21) 高原史郎, 小角幸人, 石橋道男・他:シクロスポリン特異的モノクローナル抗体を用いたラジオイムノアッセイ法による血中濃度測定の信頼性. 移植 24:565-570, 1989.

22) Gravel J, Napoli KL, Gibbons, Kahan BD:Area-under the curve monitoring of cyclosporine therapeuty:Performance of different assay methods and their target concentration. Ther. Drug. Monit. 12:8-15, 1991.

投与法

P.59 掲載の参考文献

1) Starzl TE, Marchioro TL, Waddell WR:The reversal of rejection in human renal homografts with subsequent development of homograft tolerance. Surg. Gynecol. Obstet. 117:385-395, 1963.
pubmed

2) Hume DM, Magee JH, Kaufmann HM, Rittenbury MS, Prout GR:Renal homotransplantation in man in modified recipients. Ann. Surg. 158:608-644, 1963.

3) Walker RG, d'Apice AJF, Mathew TH, Jacob C, Hardie IR et al.:Long-term follow-up of a prospective trial of low dose versus high-dose steroids in cadaveric renal transplantation. Transplant. Proc. 19:2825-2828, 1987.

4) Jabs K, Sullivan EK, Avner ED, Harmon DE:Alternate-day steroid dosing improves growth without adversely affecting graft survival or long-term graft function. Transplantation 61:31-36, 1996.

5) Operz G:Effect of the maintenance immunosuppressive drug regimen on kidney transplant outcome. Transplantation 58:443-446, 1994.

6) Strom TB:Immunosuppression in tissue and organ transplantation. Organ transplantation. Current clinical and immunological concepts. (eds. Brent L, Sells RA) , Bailliere Tindall, London, 1989, p39-56.

7) Dupont E, Schandene L, Denys C, Wybran J:Differential in vitro actions of cyclosporin, methylprednisolone, 6-mercaptopurine:Implication for drugs' influence on lymphocyte activation mechanisms. Clinical Immunolo. Immunopathol. 40:422-428, 1986.

8) Ehrich E, Lambert RE, McGuire JL:Rheumatic disorders. Clinical pharmacology. Basic principles in therapeutics 3rd edt. (eds. Melmon KL, Morrelli HF, Hoffman BB, Nierenberg DW) , McGraw-Hill Inc, New York, 1992, p475-476.

9) Keller F, Hemmen T, Schoneshofer M, Schwarz A, Offermann G:Pharmacokinetics of methylprednisolone and rejection episodes in kidney transplant patients. Transplantation 60:330-333, 1995.
pubmed

10) Stjernholm MR, Katz FH:Effects of diphenylhydantoin, phenobarbital and diazepam on the metaboIism of methylprednisolone and its hemiscucinate. J. Clin. Endocrinol Metabol 41:887-893, 1975.

11) Wassher SJ, Pennisi AJ, Malakzadeh MH, Fine RN:The adverse effects of anticonvulsant therapy on renal allograft survival. J. Pediatr. 88:134-137, 1976.

12) Peterelt LB, Meikle AW:Effectiveness of prednisolone during phenytoin therapy. Clin. Pharmacol. Ther. 22:912-916, 1977.

13) 長谷川昭:発育成長と腎移植. 小児腎移植とその問題点. 腎移植の実際. (太田和夫, 岩崎洋治, 園田孝夫編), 南光堂, 東京, 1985, p405-423.

14) McEnery PT, Gonzalez LL, Martin LW, West CD:Growth and development of children with renal transplants-Use of alternate day steroid therapy-. J. Pediatri. 83:806-814, 1973.

15) Pamela R, Patton PA, Pfaff WW:A septic bone necrosis after renal transplantation. Surgery 103:63-68, 1988.

16) Fryer Jp, Granger DK, Leventhal JR, Gillingham K, Najarian JS et al.:Steroid-related complications in the cyclosporine era. Clin. Transplantation 8:224-229, 1994.
pubmed

17) Fryer JP, Benedetti E, Gillingham K, Najarian JS, Matas AJ:Steroid-related complications in pediatric kidney transplant recipients in the cyclosporine era. Transplant. Proc. 26:91-94, 1994.
pubmed

18) Saito S, Matsuno T, Tanaka N, Orita K, Sakagami K et al.:Ocular complications in renal allograft recipients with special reference to steroid cataractogenic factor. Transplant. Proc. 28:1474-1475, 1996.
pubmed

19) Vesco L, Busson M, Bedrossian J, Bitker MO, Hiesse C et al.:Diabetes mellitus after renal transplantation. Characteristics, outcome, and risk factors. Transplantation 61:1475-1478, 1996.
pubmed

20) Fabrega A, Cohan J, Meslar P, Pollak R:Effects of steroid withdrawal on long-term renal allograft recipients with posttransplantation diabetes mellitus. Surgery 116:792-797, 1994.
pubmed

21) Hricik DE, Schulak JA:Metabolic effects of steroid withdrawal in adult renal transplant recipients. Kidney Int. 43 (suppl.):S26-S29, 1993.
pubmed

22) Arnadottir M, Berg A-L:Treatment of hyperlipidemia in renal transplant recipients. Transplantation 63:339-345, 1997.
pubmed

23) Kobashigawa JA, Kasiske BL:Hyperlipidemia in solid organ transplantation. Transplantation 63:331-338, 1997.
pubmed

24) Taler SJ, Textor SC, Canzanello VJ, Schwartz L, Porayko M et al.:Role of steroid dose in hypertension early after liver transplantation with tacrolimus (FK 506) and cyclosporine. Transplantation 62:1588-1592, 1996.
pubmed

25) Ratcliffe PJ, Dudley CRK, Higgins RM, Firth JD, Smith B et al.:Randomized controlled trial of steroid withdrawal in renal transplant recipients receiving triple immunosuppression. Lancet 348:643-648, 1996.

P.79 掲載の参考文献

1) Wideman CA:Pharmacokinetic monitoring of cyclosporine. Transplant. Proc. 15 (suppl. 1/2):3168-3175, 1983.

2) Lemaire M, Maurer G, Wood AJ:Pharmacokinetics and metabolism. Prog. Allergy 38:93-107, 1986.
pubmed

3) Beveridge T:Pharmacokinetics and metabolism of Cyclosporin A;In Cyclosporin A. Elswvier Biomedical Press, Amsterdarn, 1981.

4) Rosano TG, Freed BM, Cerilli et al.:Immunosuppressive metabolites of cyclosporinein the blood of renal allograft recipients. Transplantation 42:262, 1986.

5) Ryffel B:Biologic significance of cyclosporine metabolites. Transplant. Proc. 20 (suppl. 2):575, 1988.

6) Yee GC:Recent advances in cyclosporine pharmacokinetics, Pharmacotherapy 11:130S-134S, 1991.
pubmed

7) Yee GC, Lennon TP, Gmur DJ et al. Effect of age on cyclosporine pharmacokinetics in marrow transplant recipients. Transplant. Proc. 19:1704-1705, 1987.

8) Yee GC, Lennon TP, Gmur DJ et al.:Effect of obesity on cyclosporine disposition. Transplantation 45:649-651, 1988.
pubmed

9) 打田和治, 高木弘:死体腎移植(1). シクロスポリンの臨床. (高木弘編), 医歯薬出版, 東京, 1990, p83-94

10) Handschumacher RS, Harding MW, Rice J et al.:Cyclophilin:A specific cytosolicbinding protein for cyclosporin A. Science 226:544, 1984.

11) Liu J, Farmer JDJr, Lane WS et al.:Calcineurin is a common target of cyclophilincyclosporin A and FKBP-fk 506 complexes. Cell 66:807, 1991.

12) 高橋信弘:サイクロフィリン, FK 506結合蛋白質とシグナル伝達. 実験医学 10:1780, 1992.

13) 久野高善, 向井秀幸, 張昌徳・他:「プロテインフォスターゼと神経・免疫系カルシニューリンを中心として」実験医学 10:1238, 1992.

14) 両角國男, 山口裕編:シクロスポリンと腎-腎病理組織アトラス-. 東京医学社, 東京, 1991.

15) Canadian multicentre transplant study Group:A randomized clinical trial of cyclosporine in cadaveric renal transplantation. N. Eng. J. Med. 309:809, 1983.

16) Castro LA, Hillebrand G, Land W:Cyclosporine in patients with oligo-anuria after cadaveric kidney transplantation. Transplant. Proc. 15(suppl. 1):483, 1983.

17) Devineni R, McKenzie N, Duplan J et al.:Clinical and experimental observations. Transplant. Proc. 15(suppl. 1):479, 1983.

18) Novick AC, Ho-Hsieh H, Steinmuller D et al.:Detrimental effect of cyclosporine oninitial function of cadaver renal allografts following extended preservation. Results ofarandomized prospective study. Transplantation 42:154, 1986.

19) Rocher LL, Landis C, Dafoe DC et al.:The importance of prolonged post-transplantdialysis requirement in cyclosporine-treated renal allograft recipients. Clin. Transplant. 1:29, 1987.

20) Dumont FJ, Staruch MJ, Koprak SL et al.:The immunosuppressive and toxic effectsof FK-506 are mechanistically related:Pharmacology of a novel antagonist of FK506and rapamycin. J. Exp. Med. 176:751, 1992.

21) 打田和治, 高木弘:腎移植患者におけるHPLC全血モニタリングによるシクロスポリン免疫抑制療法. Med. Immunol. 14:598-609, 1987.

22) 打田和治, 高木弘:CYAと免疫抑制剤の併用療法のあり方. 臨床透析 8:577, 1992.

23) 打田和治:シクロスポリンの薬物動態とTDM. シクロスポリンの実際. (高木弘編), p17-30, 国際医学出版, 東京, 1996.

24) Ferguson RM, Sutherland DER, Simmons, RL, Najarian JS:Ketoconazole, Cyclosporin metabolism and renal transplantation. Lancet ii:882, 1982.

25) Jensen JC, Gugler R:Characterization of cimetidine. Interaction with liver microsomes in vitro. Arch. Pharmacol. 322:R110, 1983.

26) Daniels NJ, Dover JS, Schachter RK:Interaction between cyclosporin and rifampicin. Lancet ii:639, 1984.

27) Feeman DJ, Laupacis A, Keown P et al.:The effect of agents that alter drug metaboIizing enzyme activity on the pharmacokinetics of cyclosporin. Ann. R. Coll. Physns. Surg. Can. 17:301, 1984.

28) Burke MD, Whiting PH:The role of drug metabolism in cyclosporin A nephrotoxicity. Clin. Nephrol. 25(suppl. 1):S111, 1986.
pubmed

29) Wallwork K, McGregor CGA, Wells FC et al.:Cyclosporin and intravenous sulphadimidine and trimethoprim therapy. Lancet i:366, 1983.

30) Kelmedy MS, Deeg HJ, Siegel M et al.:Acute renal toxicity with combined use of amphotericin B and cyclogporin after marrow transplantation. Transplantation 35:211, 1983.

31) Whiting PH, Thomson AW, Simpson JG:Renal and hepatic function in rats treated with cyclosporin A in combination with gentamicin or cephalosporin antibiotics. Br. J. Exp. Pathol. 64:693, 1983.
pubmed

32) Thompson JF, Chalmers DHK, Hunnisett ABW et al.:Nephrotoxicity of trimethoprim and cotrimoxazole in renal allograft recipients treated with cyclosporin. Transplantation 36:204, 1983.

33) Morganstern GR, Powles R, Robinson B, McElwain TJ:Cyclosporin interaction with ketoconazole and melphalan. Lancet ii:1342, 1982.

34) Yee GC, McGuire TR:Pharmacokinetic drug interactions with cyclosporin. Clinical Pharmacokinetics 19:319-332 and 400-415, 1990.

35) Chan GL, Sinnott JT, Emmanuel PJ et al:Drug interactions with cyclosporine:focus on antimicrobial agents. Clinical Transplantation 6:141-153, 1992.

36) Cockburn ITR, Krupp P:An appraisal of drug interactions with Sandimmun. Transplant. Proc. 21:3845-3850, 1989.

37) Lake KD:Management of drug interactions with cyclosporine. Pharmacotherapy 11:1105-1185, 1991.

38) Merion RM, Greatorex RA, Calne RY:Delayed acute rejection episodes in cyclosporine-treated renal transplant recipients. Ann. Surg. 201(4):444-446, 1985.
pubmed

39) Tarantino A, Aroldi A, Stucchi L et al.:A randomized prospective trial comparing cyclosporine monotherapy with triple-drug therapy in renal transplantation. Transplantation 52(1):53-57, 1991.
pubmed

40) Brinker KR, Dickerman RM, Gonwa TA et al.:A randomized trial comparing double-drug and triple-drug therapy in primary cadaveric renal transplants. Transplantation 50(1) 43-49, 1990.
pubmed

41) Martin DC, Tertzakian G, Ruzics E:Comparison of 2-drug and 3-drug immunosuppression for cadaveric renal transplantation. J. Urol. 143(5):900-901, 1990.
pubmed

42) Thayer C, Bartlett ST, Ward RE:Increased septic complications with three-drugsequentjal immunosuppression for cadaver renal transplants. Am. J. Surg. 160(6):614-617, 1990.
pubmed

43) Bowman JS 3d, Angstadt JD, Waymack JP et al.:Acomparison of triple-therap ywith double-therapy immunosuppression in cadaveric renal transplantation. Transplantation 53(3):556-559, 1992.

44) Norman DJ, Kahana L, Stuart FP Jr:A randomized clinical trial of induction therapywith OKT 3 in kidney transplantation. Transplantation 55(1):44-50, 1993.

45) Opelz G:Collaborative transplant study-10-year report. Transplant. Proc. 24(6):2342-2355, 1992.
pubmed

46) Land W:Procedures and results in renal transplantation:Munich transplant centre 1986. Optimal Use of Sandimmun in Organ Transplantation. (ed. Land W), Springer, Berlin Heidelberg New York London Paris Tokyo, p 20-22, 1987.

47) Diethelm AG, Laskow DA, Hudson SL et al.:Benefits of quadruple immunosuppressive therapy in recipients of living related donor kidneys. A review of 855 operations. Ann. Surg. 215(6):606-616, 1992.
pubmed

48) 打田和治, 高木弘:シクロスポリン. 腎と透析 39:847-853, 1995.

49) Hardie IR, Tiller DJ, Mahony JF et al.:Optimal combination of immunosuppressive agents for renal transplantation:first report of a multicentre, randomised trial comparing cyclosporine + prednisolone with cyclosporine + azathioprine and with triple therapy in cadaver renal transplantation. The Australian Collaborative Trials Committee. Transplant. Proc. 25(1, Book I):583-584, 1993.

50) Canadian multicentre transplant study Group:A randomized clinical trial of cyclosporine in cadaveric renal transplantation. N. Eng. J. Med. 309:809, 1983.

51) Castro LA, Hillebrand G, Land W:Cyclosporine in patients with oligo-anuria after cadaveric kidney transplantation. Transplant. Proc. 15(suppl. 1):483, 1983.

52) Devineni R, McKenzie N, Duplan J et al.:Clinical and experimental observations. Transplant. Proc. 15(suppl. 1):479, 1983.

53) Novick AC, Ho-Hsieh H, Steinmuller D:Detrimental effect of cyclosporine on initial function of cadaver renal allografts following extended preservation. Results of arandomized prospective study. Transplantation 42:154, 1986.

54) Rocher LL, Landis C, Dafoe DC et al.:The importance of prolonged post-transplant dialysis requirement in cyclosporine-treated renal allograft recipients. Clin. Transplant. 1:29, 1987.

55) Kahan BD, Flechner g. M, Lorber MI et al.:Complications of cyclosporine-prednisone immunosuppression in 402 renal allograft recipients exclusively followed at a single center for from one to five years. Transplantation 43:197. 204, 1987.

56) Bakran A, Johnson RW, Dyer PA, Mallick NP, Gokal R.:Triple therapy improves the survival of cadaver renal allografts affected by acute tubular necrosis. Transplant. Proc. 21(1 Pt 2):1278-1279, 1989, Feb.

57) Gonwa TA, Nghiem DD, Schulak JA et al.:Cyclosporine use in early graft dysfunction. Transplant. Proc. 18(2 suppl. 1):104-112, 1986.

58) Pecorella I, Ciardi A, Di Febo M et al.:Cytologic analysis of CyA nephrotoxicity:double vs triple drug therapy in kidney grafted patients. Transplant. Proc. 24(5):1700-1703, 1992.
pubmed

59) Cacciarelli TV, Sumrani N, DiBenedetto A et al.:The influence of recovery of early function on long-term renal allograft outcome. Transplant. Proc. 24(5):1764-1766, 1992.
pubmed

60) Grey D, Shepherd H, Daar A, Oliver DG, Norris PJ:Oral versus intravenous high dose steroid treatment of renal allograft rejection. Lancet 1:117, 1978.

61) Kountz SL, Cohn R:Initial treatment of renal allografts with large intrarenal doses of immunosuppressive drugs. Lancet i:338340, 1969.

62) Danovitch GM:Prevention and treatment A:glucocorticoids and azathioprine. Textbook of Nephrology. (ed. Massery SG), Williams & Tilkins, 1995, p1645-1648.

63) Matas AJ, Tellis VA, Quinn T et al.:ALG treatment of steroid-resistant rejectiorl in patients receiving cyclosporine. Transplantation 41:579, 1986.
pubmed

64) Richardson AJ, Iliggins RM, Liddington M et al.:Antilymphocyte globulin for steroid resistant rejection in renal transplant recipients immunosuppressed with triple therapy. Transplant. Int. 2:27, 1989.)

65) Mochon M, Kaiser B, Pakmer JA, Polinski M, Flynn JT, Caputo GC, Baluarte HJ:Evaluation of OKT-3 monoclonal antibody and antilymphocyte globulin in the treatment of steroid-resistant acute rejection in pediatric renal transplants. Pediatr Nephrol. 7:259-262, 1993.

66) Hirsch RL, Layton PC, Barners LA:Orthoclone OKT 3 treatment of acute renal allograft rejection in patients. Transplant. Proc. 19(suppl. 1):32, 1987.

67) Alergre ML et al.:Evidence that pentoxifylline reduces anti-CD3 monoclonal anti-body-induced cytokine release syndrome. Transplantation 52:674, 1991.

68) Houle AM, McLoire GA, Churchill BM, Khoury AE, Harvey E, Hebert D:Rapid development of an immunoblastic lymphoma and death in children following cadaveric renal transplantation. J. Pediatr. Surg. 27:626-628, 1992.

69) 雨宮浩, 鈴木誠一, 太田和夫, 高橋公太, 園田孝夫・他:新しい免疫抑制剤, NKT-01(デオキシスパガリン)の腎移植後の拒絶反応に対する治療効果-前期第II相臨床試験-. 移植 26:604-614, 1991.

70) 雨宮浩, 太田和夫, 園田孝夫, 深尾立・他:腎移植後の拒絶反応治療に対するNKT-01の私的投与量設定のための臨床試験-後期第II相臨床試験-. 移植 26:615-628, 1991.

71) 雨宮浩, 田口善雄, 深尾立, 礒野可一, 尾本良三, 太田和夫・他:腎移植後の難治性拒絶反応に対するNKT-01の治療効果-治験基準外症例に対する一般臨床試験-. 基礎と臨床 25:3501-3508, 1991.

72) Ochiai T, Nagata M, Nakajima K, Suzuki T, Sakamoto K, Enomoto K, Gunji Y, Uematsu T, Goto T, Hori S, Kenmochi T, Nakagouri T, Asano T, Isono K, Halnaguchi K, Tsuchida H, Nakahara K, Inamura N, Goto T:studies of the effects of FK 506on renal allografting in beagle dog. Transplantation 44:729-733, 1987.

73) Jordan ML, Shapiro R, Jensen CWB, Scantlebury VP, Fung J, Tzakis A, McCauley J, Jain A, Demetris J, Randhawa P, Simrnolls RL, Hakala TR, Starzl TE:FK 506conversion of renal allografts failing cyclosporine immunosuppression. Transplant. Proc. 23:3078-3081, 1991.

74) FK 506腎移植研究会, 高橋公太, 太田和夫, 岩崎洋治, 高木弘, 園田孝夫:腎移植におけるFK 506(tacrolimus)の救済的治療試験成績. 移植 29:682-697, 1994

75) Platz KP, Eckhoff D, Bechstein WO, Suzuki Y, Sollinger HW:RS-61443 for reversal of acute rejection in canine renal allografts. Surgery 110:736-741, 1991.

76) Morris RE, Hoyt EG, Murphy MP, Eugui EM, Allison AC:Mycophenolic Acid Morpholinoester(RS-61443) is a new immunosuppressant that prevents and halts heart allograft rejection by selective inhibition of T-and B-cell purine synthesis. Transplant. Proc. 22:1659-1662, 1990.

77) Allison AC:Approaches to the design of immunosuppressive agents. The Molecular Biology of Immunosuppression. (ed. Thomson AW), John Wiley & Sons Ltd., England, 1992, p181-209.

78) Sollinger HW, Deierhoi MP, Belzer FO:RS-61443-A phase 1 clinical trial and pilotrescue study. Transplant. Proc. 53:428-432, 1992.

79) RS-61443 腎移植研究会, 打田和治, 高橋公太, 落合武徳, 磯野可一, 安村忠樹, 岡隆宏, 鈴木盛一, 雨宮浩, 石橋道男, 高原司郎, 奥山明彦, 小椋陽介, 高木弘, 園田孝夫, 太田和夫:腎移植後における難治性拒絶反応に対するRS-61443(mycophenolate mofetil)の治療効果の検討-第2相臨床試験-. 移植 32:149-158, 1997.

80) Fassbinder W, Scheuermann EH, Hanke P, Bechstein PB, Ernst W, Stutte HJ, Schoeppe W:Improved graft prognosis by treatment of steroid resistance rejection with rabbit antithymocyte globulin and/or plasmaphoresis. Transplant. Proc. 17:2769-2772, 1985.

81) Cardella CJ, Sutton DMC, Uldall PR, Cook GT, deVeber GA:Factors influencing the effect of intensive plasma exchange on acute transplant rejection. Transplant. Proc. 17:2777-2778, 1985.

82) Brophy D et al.:Acute tubular necrosis after renal transplantation. Transplantation 29:245-248, 1980.
pubmed

83) Van Es A et al.:Effect of warm ischemia time and HLA(A and B)matching on renaIcadaveric graft survival and reject｛on episodes. Transplantation 36:255-258, 1983.

84) Morris PJ, Chapman JR, Allen RD et al.:Cyclosporin conversion versug. conventional immunosuppression:long-term follow-up and histological evaluation. Lancet 1(8533):586-591, 1987.

85) Hall BM, Tiller DJ, Hardie I et al.:Comparison of three immunosuppressive regimens in cadaver renal transplantation:long-term cyclosporine, short-term cyclosporine followed by azathioprine and prednisolone, and azathioprine and prednisolonewithout cyclosporine. N. Engl. J. Med. 318(23):1499-1507, 1988.
pubmed

86) Weimar W, Versluis DJ, Wenting GJ et al.:Prolonged cyclosporine therapy to induce solid engraftment after renal transplantation. Transplant. Proc. 19(1)(Book III):1998-1999, 1987.

87) Maddux MS, Veremis R, Pollak R et al.:Conversion from cyclosporine to azathioprine improves renal function without increased risk of graft failure. Transplant. Proc. 19(1)(Book III):2007-2009, 1987.

88) Tegzess AM, van Son WJ, Beelen JM et al.:Improvement of renal function after conversion from cyclosporine only to prednisolone-azathioprine followed by lateonset graft failure in renal transplant patients. Transplant. Proc. 19(1) (Book II):2000-2004, 1987.

89) Veitch PS, Taylor JD, Feehally J et al.:Elective conversion from cyclosporine to azathioprine:Long-term follow-up. Transplant. Proc. 19(1) (Book III):2017, 1987.

90) Terasaki PI, Cecka JM, Gjertson DW et al.:High survival rates of kidney transplantsfrom spousal and Iiving unrelated donors. N. Engl. J. Med. 333(6):333-336, 1995.

91) Mackenzie HS, Tullius SG, Heemann UW et al.:Nephron supply is a major determinant of long-term renal allograft outcome in rats. J. Clin. Invest. 94:2148-2152, 1994.
pubmed

92) Alexander JW, Bemett LE, Breen TJ:Effect of donor age on outcome of kidney transplantation. Transplantation 57(6):871-876, 1994.

93) Soulillou JP:Panel discussion:Future immunosuppressive protocols. Transplant. Proc. 28(6)(suppl.1):41-44, 1996.

P.108 掲載の参考文献

1) Ochiai T, Nakajima K, Nagata M et al.:Studies of the induction and maintenace of long terln graft acceptance by treatment with FK 506in heterotopic cardiac allotrans- plantation in rats. Transplantation 44:734-738, 1987.

2) Starzl TE, Todo S, Furlg J et al.:FK 506for liver, kidney, and pancreas transplantation. Lancet II 8670:1000-1004, 1989.

3) Japanese FK 506Study Group:Japanese study of FK 506on kidney transplantation:The benefit of monitoring the whole blood FK 506concentration. Tranplant. Proc. 23:3085-3088, 1994.

4) Japanese FK 506Study Group:Japanese study of FK 506on kidney transplantation:Results of late phase II study. Transplant. Proc. 25:649-654, 1993.

5) Japanese FK 506Study Group:Two-year follow-up study of the efficacy and safety of FK 506in kidney trasplant patients. Transplant. Int. 7(suppl. 1):247-251, 1994.

6) Kino T, Hatanaka H, Hashimoto M et al.:FK 506, a novel immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation, and physicochemical and biological characteristics. L Antibiotics 40:1249-1255, 1987.

7) Mccaffrey PG, Perrino BA, Soderling TR et al.:NF-ATP, a T lymphocyte DNA-binding protein that is a target for calcinurin and immunosuppressive drugs. J. Bio. Chem. 268:3747-3752, 1993.

8) 高橋公太:免疫学的ハイリスクの腎移植-ABO血液型不適合腎移植におけるtacrolimus (FK 506)の使用経験-. 泌尿器科学の最近の進歩-1996. (藤田公生編), 浜松医科大学, 浜松, 1996, p13-22.

9) Pirsch JD, Miller J, Deierhoi MH, Vincenti F, Filo RS, The FK 506Kidney Transplant Study Group:Acomparison of tacrolimus(FK 506)and cyclosporine for immunosuppression after cadaveric renal-transplantation. Transplantation 63:977-983, 1997.

10) Hisatoshi A, Kimura M, Maeda M et al.:Toxicity of polyoxyethylene hydrogenated castor oil 60(HCO-60)in experimental animals. J. Toxico. Sci. 18(suppl. 3):1-9, 1993.

11) 高橋公太:タクロリムス(FK 506). 泌尿器外科 10:319-326, 1997.
Medical*Online

12) 橋田亨, 池西政幸, 虎口美典・他:マイクロパーティクルEIA法によるタクロリムスの血中濃度モニタリング. TDM研究 11:18-22, 1994.
Medical*Online

13) 太田和夫監修, 高橋公太編:新しい免疫抑制剤抗リンパ球モノクローナル抗体. 医歯薬出版, 東京, 1991, p1-128.

14) Mangel AK, Grocse GH, Sinclair M et al.:Acquried hemolytic anemia due to "auto" -anti-A or "auto" -anti-B induced by group D homograft in renal transplant recipients. Transfusion 24:201-205, 1984.

15) 水口潤, 高橋公太, 太田和夫・他:抗A, 抗自己抗体の出現により急激な血管内溶血をきたした腎移植の1症例. 腎と透析 17:968-970, 1984.

16) 太田和夫, 阿岸鉄三監修, 高橋公太編:ABO血液型不適合腎移植. 日本医学館, 東京, 1991, p1-119.

17) Takahashi K:A review of humoral rejection in ABO-incompatible kidney transplantation, with local(intrarenal DIC)as underlying condition. Acta Medica et Biologica 45:95-102, 1997

18) 高木弘編:シクロスポリンの実際. 国際図書出版, 東京, 1996, p1-412.

19) RS 61443 invest. igation Committee-Japan:Pilot study mycophenolate mofetil(RS-61443)in the prevention of acute rejection following renal transplantation in Japanese patients. Transplant. Proc. 27:1421-1424, 1995.

20) Amemiya H, 9. uzuki S, Takahashi K et al.:Anovel resue drug, 15 deoxyspergualin. Transplantation 49:377. 343, 1990.

21) Salamon DJ, Ramsey G, Starzl T et al.:Anti-A production by a group O spleen transplanted to a group A recipient. Vox Sangunis 48:309-312, 1985.

22) 田辺一成, 高橋公太, 阿岸鉄三・他:前感作抗体陽性例に対する積極的腎移植の試み. 移植 25:127-132, 1990.

23) 若月俊二, 今井智之, 高橋公太・他:2歳ドナーからの小児死体腎移植の1例. 移植 32:303-307, 1997.
Medical*Online

24) FK 506研究会:腎移植におけるFK 506(tacrolimus)の救済的治療試験成績. 移植 29:682-697, 1994.

25) 筒井寿基, 斎藤和英, 高橋公太・他:シクロスポリンをタクロリムスに変更したことにより高脂血症が改善傾向を示した生体腎移植の1例. 今日の移植 10:461-463, 1997.

26) FK 506研究会:腎移植におけるFK 506(tacrolimus)の第III相比較試験成績. 移植 29:682-697, 1994.

27) Mue11er AR, Platz KP, Bechstein WO et al.:Neurotoxicity after orthotopic liver transplantation, A comparison between cyclosporine and FK 506. Transplantation 58:155-170, 1994.

28) 高橋公太編:臓器移植におけるサイトメガロウイルス感染症. 日本医学館, 東京, 1997.

P.122 掲載の参考文献

1) Calne RY, Alexandre GPJ, Murry JE:Astudy of the effects of drugs in prolonging survival of homologous renal transplants in dogs. Ann. N Y Acad. Sci. 99:743-761, 1962.

2) Murry JE, Merrill Jp, Harrison JH et al.:Prolonged survival of human kidney homografts by immunosuppressive drug therapy. New Engl. J. Med. 268:1315-1323, 1963.

3) Calabresi P, Parks REJ:Antiproliferative agents and drugs used for immunosuppression. The pharmacological bases of theraputics. (eds. Gilman AG, Goodman LS, Rall TW, Murad F), Macmillan Publishing Co., New York, 1985, p 1247-1306.

4) Schutz E, Gummert J, Armstrong VW, Mohr FW, Oellerich M:Azathioprine pharmacogenetics:The relationship between 6-thioguanine nucleotide and thiopurine methyltransferase in patients after heart and kidney transplantation. Eur. J. Clin. Chem. Biochem. 34:199-205, 1996.

5) Winkelstein A:Immunopharmacology, Pharmacology. (eds. Smith CM, Raynard AM), WB Saunders Co., Philadelphia, 1992, p 964-983.

6) 橘正道:プリンおよびピリミジンヌクレオチドの代謝. ハーバー生化学. (上代淑人監訳), 丸善, 東京, 1993, p395-410.

7) Katz P, Fauci AS:Immunosuppressives and immunoadjuvants. Immunological diseases, fouthed. (eds. Samter M, Talmage DW et al.), Little Brown and Company, Boston, Tronto, 1988, p 675-698.

8) Bach JF:The mode of action of immunosuppressive agents. North-Holland Research Monographs. Frontiers of Biology, North-Holland 41:150, 1975.

9) Taylor AEM, Shuster S:Skin cancer after renal transplantation:The causal role of azathioprine. Acta Derm. Venereol. 72:115-119, 1992.

10) Refabert L, Sinnassamy P, Leroy B, Fauroux B, Blic J et al.:Azathioprine-induced pulumonary haemorrhage in a child after renal transplantation. Pediatr. Nephrol. 9:470-473, 1995.

11) 井上均, 朴勺, 金哲將, 牛田博, 小西平, 住吉唯夫:アザチオプリンにより間質性肺炎をきたしたと考えられた献腎移植の1例. 臨泌 50:865-868, 1996.

12) Bedrossian CWM, Sussman J, Conklin RH, Kahan B:Azathioprine-assosiated interstitial pneumonitis. Am. J. Clin. Pathol. 82:148-154, 1984.

13) 安村忠樹, 岡隆宏:アザチオプリン. 腎と透析 39:855-861, 1995.

14) 今村貞夫:免疫抑制剤. 皮膚病診療 14:263-269, 1992.

15) 根来茂, 片田圭宣:アザチオプリン, シクロスホスファミドなどの細胞障害製薬剤. 治療学 26:177-182, 1992.

16) 雨宮浩:アザチオプリン. 腎と透析臨時増刊号:531-533, 1989.

17) 白髪宏司, 伊藤克己:免疫抑制剤. 小児科臨床 38:851-960, 1985.
Medical*Online

18) Bach JF, Dardenne M:The metabolism of azathioprine in renal failure. Transplantation 12:253, 1971.

19) Bach JF, Dardenne M:Serum immunosuppressive activity of azathioprine in normal subjects and patients with liver disease. Proc. Roy. Soc. Med. 65:260, 1972.
pubmed

20) 藤原郁也, 安村忠樹, 荒川幸平, 鈴木茂敏, 中路啓介・他:腎移植後の高尿酸血症と移植腎生着率への影響. 移植 28:596-603, 1991.

21) 安村忠樹, 荒川幸平, 吉村了勇, 中井一郎, 濱島高志・他:シクロスポリン, アザチオプリン, プレゾニドロン3剤併用療法と移植腎の長期予後. 移植 26:363-368, 1991.

22) 安村忠樹, 大阪芳夫, 中井一郎, 吉村了勇・他:移植腎慢性拒絶後における透析再導入患者の予後と合併症. 透析会誌 27:89-94, 1994.

23) 安村忠樹, 大森吉弘, 相川一郎, 荒川幸平・他:シクロスポリン使用症例における長期予後とlate rejection. 移植 23:193-199, 1988.
Medical*Online

24) 秋山暢夫, 枝国節雄, 井口宏:Combination immunosuppression を用いた腎移植例の検討. 移植 22:362-372, 1987.
Medical*Online

25) 宮原茂, 村上雅巳, 宮崎文男, 松岡啓, 野田進士・他:生体腎移植におけるcyclosporin, azathioprine, steroidによる3剤併用免疫抑制療法の検討. 西日泌尿 51:1843-1846, 1989.

26) 内田久則・他:腎移植におけるcyclosporin, mizoribine, steroid 3剤合併投与法. 腎と透析 22:189-195, 1987.

27) 鈴木盛一, 林良輔, 渡辺浩志, 雨宮浩:腎移植におけるcyclosporin, mizoribine, steroid, ALGの4剤併用療法. 移植 23:149-156, 1988.

28) European Multicentre Trial Group:European multicentre trial of cyclosporine in renal transplantation:10year follow up. Transplant. Proc. 25:527-529, 1993.

29) Thiel G, Bock A, Spondlin M, Brunner FP et al.:Long-term benefit and risks of cyclosporine A therapy:An analysis at ten years. Kidney Int. 45:1793-1795, 1994.

30) Mihatsch ML, Morozumi K, Strrom EH, Ryffel B et al.:Renal transplant morphology after long-term therapy with cyclosporine. Transplant. Proc. 27:39-42, 1994.

31) Pirsch JD, D'Alessandro AM, Knechtle SJ, Kalayoglu M et al.:Renal transplantation in the cyclosporine era. Transplant. Proc. 26:2458-2489, 1994.

32) Opelz G:For the collaborative transplant study-10-year report. Transplant. Proc. 24:2342-2356, 1992.
pubmed

33) 日本移植学会:腎移植臨床登録集計報告(1994. 中間報告). 移植 30:428-449, 1995.
Medical*Online

34) Hollander A, Saase J, Kootte A, Drop W, Bocel H et al.:Beneficial effect of civersionfrom cyclosporin to azathioprine after kidney transplantation. Lancet 345:610-614, 1995.

35) Shapiro R, Jordan ML, Scanlebury VP, Vivas C, Fung JJ et al.:Randomized trial of FK 506/prednisone vs FK 506/azathioprine/prednisone after renal transplantation. Transplant. Proc. 25:669-672, 1993,

36) Shapiro R, Jordan ML, Scanlebury VP, Vivas C, Fung JJ et al.:A prospective, randomized trial of FK 506/prednisone vs FK 506/azathioprine/prednisone in renal transplant patients. Transplant. Proc. 27:814-817, 1995.

P.141 掲載の参考文献

1) European Multicentre Trial Group:Cyclosporin in cadaveric renal transplantation:one-year follow-up of a multicentre trial. Lancet 2:986-989, 1983.
pubmed

2) European Multicentre Trial Group:Cyclosporin in cadaveric renal transplantation:5-year follow-up of a multicentre trial. Lancet 2:506-507, 1987.

3) Beveridge T, Calne RY for European Multicentre Trial Group:Cyclosporine(San-dimmune)in cadaveric renal transplantation:ten-year follow-up of a multicenter trial. Transplantation 59:1568-1570, 1995.

4) 高橋公太:免疫抑制療法-A. 導入期免疫抑制療法-. シクリスポリンの実際. (高木弘編), 国際醫學出版, 東京, 1996, p57-78.

5) Sollinger HW for The US. Renal Transplant Mycophenolate mofetil Study Group:Mycophenolate Mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. Transplantation 60:225-232, 1995.

6) Mizuno K, Tsujino M, Takada M, Hayashi M, Atsumi K et al.:Studies on bredinin. I. Isolation, characterization and biological properties. J. Antibiotics 27:775782, 1974.

7) Koyama H, Tsuji M:Genetic and biochemical studies on the action and cytotoxic mechanism of bredinin, a potent inhibitor of purine biosynthesis in mammalian cells. Biochem. Pharmacol. 32:3547-3553, 1983.

8) 佐川史郎, 石橋道男, 有馬正明, 宇佐美道之, 長船匡男・他:新しい免疫抑制剤の開発に関する研究-第1報:犬同種腎移植におけるBredininの免疫抑制効果-. 移植 13:271-276, 1978.

9) Uchida H, Yokota K, Akiyama N, Masaki Y, Aso K et al.:Effectiveness of a new drug, bredinin, on canine kidney allotransplant. Transplant. Proc. 11:865-870, 1979.
pubmed

10) 佐川史郎, 市川靖二, 井原英有, 石橋道男, 有馬正明・他:腎移植患者におけるHE-69(Bredinin)の安全性試験について. 移植 17(suppl.):727-736, 1982.
Medical*Online

11) Hager PW, Collart FR, Huberman E, Mitchell BS:Recombinant human inosine monophospate dehydrogenase type I and typeII proteins:purification and characterization of inhibitor binding. Bioch. Pharmacol. 49:1323-1329, 1995.

12) Kusumi T, Tsuda M, Katsunuma T, Yamamura M:Dual inhibitory effect of bredinin. Cell Biochem. Func. 7:201-204, 1988.

13) 村瀬潤一, 水野公雄, 川井邦男, 西海秀作, 小林洋四郎・他:Bredininのラットにおける吸収, 分布, 代謝および排泄. 応用薬理 15:829-835, 1978.

14) Ichikawa Y, Ihara H, Takahara S, Takada K, Shrestha GR et al.:The immunosuppressive mode of action of mizoribine. Transplantation 38:262-267, 1984.
pubmed

15) Takada K, Nakae H, Asada S, Ichikawa Y, Fukunishi T:Rapid method for the high-performance liquid chromatographic determination of bredinin in human serum. J. Chromatogr. 222:156-159, 1981.

16) Ihara H, Shinkuma D, Nojima M, Koike H, Yabumoto H et al.:Clinical significance of blood level monitoring of mizoribine in kidney transplantation. Transplant. Proc. 26:2029-2031, 1994.
pubmed

17) Okubo M, Kamata K, Yokota K, Uchida H, Masaki Y et al.:Effect of bredinin on cellular and humoral immune responses and on canine kidney allograft survival. Transplant. Proc. 12:515-519, 1980.
pubmed

18) 稲生綱政:腎移植におけるBredininの免疫抑制効果-BREDININ 研究会集計-. 移植 17(suppl.):547-561, 1982.
Medical*Online

19) Suzuki S, Hijioka T, Sakakibara I, Amemiya H:The synergistic effect of cyclosporine and mizoribine on heterotopic heart and partial-1ung transplantation in rats. Transplantation 43:743-744, 1987.

20) Terai C, Hakoda M, Yamanaka H, Kamatani N, Kashiwazaki S:Differntial cytotoxic effects of mizoribine and its aglycone on human and murine cells and no normal and enzyrne-deficit human cells. Bioch. Pharmacol. 50:1099-1102, 1995.

21) Kokado Y, Ishibashi M, Jiang H, Takahara S, Sonoda T et al.:Low-dose ciclosporin mizoribine and prednisolone in renal transplantation:A new triple-drug therapy. Clin. Transplant. 4:191-197, 1990.

22) 尊田和徳, 高橋公太, 田辺一成, 太田和夫:腎移植患者のミゾリビン至適投与量の検討. Therapeutic Research 16:300-305, 1995.

23) Sato K, Matsuzawa K, Tadokoro F, Kakita A, Okubo M et al.:Studies of immunosuppression with quadruple regimen treatment(cyclosporine, mizoribine, prednisolone, and antilymphocyte globulin)in cadaveric and living-related donor renal allotransplantation. Transplant. Proc. 24:1383-1385, 1992.
pubmed

24) Takeuchi N, Oshima S, Matsuura O, Ono Y, Katoh N et al.:Immunosuppression with low-dose cyclosporine, mizoribine, and steroids in living-related kidney transplantation. Transplant. Proc. 26:1907-1909, 1994.

25) 柏崎禎夫, 近藤啓文, 小池隆夫, 斎藤輝信, 粕川禮司・他:慢性関節リウマチに対するブレディニン(R)錠の用量比較試験-多施設共同研究による市販後臨床試験-. 炎症 16:269-289, 1996.
Medical*Online

26) Davison JM:Dialysis, transplantation, and pregnancy. Am. J. Kid. Dis. 17:127-132, 1991.
pubmed

27) 安村忠樹, 佐川史郎, 秋山隆弘, 市川靖二, 井原英有・他:ミゾリビン投与腎移植患者の妊娠出産:第8回ミゾリビン移植検討会における調査報告. 移植 32:59-66, 1997.

拒絶反応治療薬

P.170 掲載の参考文献

1) Billingham RE, Krohn PL, Medawar PB:Effects of cortisone on survivaI of skin homografts in rabbits. Br. Med. J. 1:1157-1163, 1951.

2) Zukoski CF, Callaway JM, Rhea WG:Tolerance to a canine renal homograft induced by prednisolone. Sur. Forum. 14:208-210, 1963.

3) Goodwin WE, Kaufman JJ, Mims MM, Turner RD, Glassock R et al.:Human renal transplantation clinical experience of renal homotransplantation. J. Urol. 89:13-24, 1963.

4) Bell PR, Briggs JD, Calman KC, Paton AM, Wood RF et al.:Reversal of acute clinical and experimental organ rejection using large doses of intravenous pred- nisolone. Lancet 1:876-880, 1971.

5) Turcotte JG, Feduska NJ, Carpenter EW, McDonald FD, Bacon GE:Rejection crises in human renal transplant recipients:control with high dose methylprednisolone therapy. Arch. Surg. 105:230-236, 1972.
pubmed

6) Gray D, Shepherd H, Daar A, Oliver DO, Morris PJ:Oral versus intravenous high-dose steroid treatment of rerlal allograft rejection. The big shot or not? Lancet 1:117-118, 1978.
pubmed

7) Kauffman HM Jr., Stromstad SA, Sampson D, Stawicki T:Randomized steroid therapy of human kidney transplant rejection. Transplant. Proc. 11:36-38, 1979.

8) Orta-Sibu N, Chantler C, Bewick M, Haycock G:Comparison of high-dose intravenous methylprednisolone with low. dose oral prednisolone in acute renal allograft rejection in children. Br. Med. J. 285:258-260, 1982.

9) European Multicentre Trial:Cyclosporine in cadaveric renal transplantation:one year follow-up of a multicentre trial. Lancet 2:986-989, 1983.
pubmed

10) Shield CF, Cosimi AB, Tolkoff. Rubin NE:Use of antilymphocyte globulin for reversal of acute allograft rejection. Transplantation 28:461-464, 1979.

11) Ortho Multicentre Transplant Study Group:A randomized clinical trial of OKT 3 monoclonal antibody for acute rejection of cadaveric renal trang. plants. N. Engl. J. Med. 313:337-342, 1985.

12) 佐藤文三:免疫抑制物質とその分子的作用機序, ステロイド・最新医学 50:2237-2242, 1995.

13) シクロスポリン研究会:多施設協同研究による腎移植におけるシクロスポリンの臨床評価に関する研究, 日本移植学会雑誌 20(suppl.):399-421, 1985.

14) 大島伸一:社会保険中京病院における腎移植20年の経験, 日泌会誌 85:29-31, 1994.

15) 絹川常郎, 服部良平, 大島伸一, 松浦治, 竹内宣久・他:死体腎移植後に発生する急性拒絶反応に対するモノクローナル抗体OKT3投与の長期成績への影響について. 日泌会誌 84:1851-1856, 1993.

16) Delmonico FL, Cosimi AB:Monoclonal antibody treatment of human allograft recipients, Surg, Gynecol, Obst, 166:89-98, 1988,

17) Thistlethwaite JR Jr, , Gaber Stuart JK, Mayers JT:Complications and monitoring of OKT 3 therapy, Am, J, Kidney Dis, 11:112-119, 1988,

18) Thompson JF, Chalmers DH, Wood RF, Kirkham SR, Morris PJ:Sudden death following high-dose intravenous methylprednisolone, Transplantation 36:594-596, 1983,
pubmed

19) Walker RG, d'Apice AJF, Mathew TH, Jacob J, Haedie IR et al, :Long-term follow-up of a prospective trial of low-dose versus high dose steroids in cadaveric renal transplantation, Trasnplant, Proc, 19:2825-2828, 1987,

20) Conn HO, Biltzen BL:Nonassociation of adrenocorticosteroid therapy and peptic ulcer, N, Engl. J, Med, 294:473-479, 1976,

21) Feduska NJ, Amend WJ, Vincenti F, Melzer JS, Duca R et al, :Peptic ulcer disease in kidney transplant recipients, Am, J, Surg, 148:51-57, 1984,
pubmed

P.205 掲載の参考文献

1) Waksman BH, Arbouys S, Arnason BG:The use of specific lymphocyte antisera to inhibit hypersensitive reactions of the "delayed" type, J, Exp, Med, 114:997-1033, 1961,
pubmed

2) Woodruff MFA, Anderson NF:Effect of lymphocyte depletion by thoracic duct fistula and administration of antilymphocyte serum on the survival of skin homo-grafts in rats, Nature 200:702, 1963,

3) Starzl TE, Marchioro TL, Porter KA, Iwasaki Y, Cerilli, GJ:The use of heterologous antilymphoid agents in canine renal and liver homotransplantation and in human renal homotransplantation, Surg, Gynec, Obstet, 124:301-318, 1967,
pubmed

4) 河野嘉文, 高上洋一, 渡辺力, 二宮恒夫, 黒田泰弘:抗リンパ球グロブリン(ALG)のin vitro リンパ球毒性と刺激性に関する製剤間の比較検討, 臨床血液 30:327-331, 1989.

5) Gantenbein H, Bachmann P, Huynh U, Steinhauslin F, Weinreich T et al.:Comparison of two antilymphocyte globulins replacing cyclosporin A after first kidney allotransplantation and prolonged graft ischemia, Clin, Transplantation 10:384-385, 1996,
pubmed

6) Bourdage JS, Hamlin DM:Comparative polyclonal antithymocyte globulin and antilymphocyte/antilymphoblast globulin anti-CD antigen analysis by flow cytometry, Transplantation 59:1194-1200, 1995,
pubmed

7) 岩崎洋治:抗リンパ球グロブリン. 腎と透析 27(臨時増刊号):539-540, 1989.

8) Ochiai T, Ahmed A, Strong DM, Scher I, Sell KW:Specificity and immunosuppressive potency of a rabbit antimouse T cell-specific antiserum, Transplantation 20:198-210, 1975,
pubmed

9) Najarian JS, Simmons RL, Condie RM, Thompson EJ, Fryd DS et al, :Seven years experience with antilymphoblast globulin for renal transplantation from cadaver donors, Ann, Surg, 184:352-367, 1976,
pubmed

10) Wechter WJ, Morrell RM, Bergan J, Rosenberg JC, Turcotte J et al, :Extended treatment with antithymocyte globulin(ATGAM)in renal allograft recipients, Trans plantation 28:365-367, 1979,

11) Novick AC, Braun WE, Steinmuller D, Buszta C, Greenstreet R et al, :A controlled randomized double-blind study of antilymphoblast globulin in cadaver renal transplantation, Transplantation 35:175-179, 1983,

12) Slakey DP, Johnson CP, Callaluce RD, Browne BJ, Zhu Y et al.:Aprospective randomized comparison of quadruple versus triple therapy for first cadaver trans- plants with immediate function. Transplantation 56:827-831, 1993.

13) 刑部恒男, 佐藤光史, 刑部東治, 今井潔, 瀧島常雅・他:屍体腎移植における多剤併用免疫抑制療法の比較検討. 移植 26:465-475, 1991.
Medical*Online

14) 今西正昭, 禰宜田正志, 池上雅久, 西岡伯, 石井徳味・他:シクロスポリンを用いた多剤併用による腎移植後初期免疫抑制法の検討. 日泌尿会誌 82:907-913, 1991.

15) 高橋公太, 阿岸鉄三, 大場忍, 田辺一成, 八木沢隆・他:ABO 血液型不適合間生体腎移植13例の経験. 移植 26:95-104, 1991.
Medical*Online

16) Shield CF III, Cosimi AB, Tolkoff-Rubin N, Rubin RH, Herrin J et al.:Use of antithymocyte globulin for reversal of acute allograft rejection. Transplantation 28:461-464, 1979.

17) Filo RS, Smith EJ, Leapman SB:Therapy of acute cadaveric renal allograft rejection with adjunctive antithymocyte globulin. Transplantation 30:445-449, 1980.
pubmed

18) 東間紘, 高橋公太, 寺岡慧, 中沢速和, 八木沢隆・他:急性拒絶反応に対する抗リンパ球グロブリン(ALG)パルス療法について. 移植 19:192-200, 1984.
Medical*Online

19) 秋山隆弘:拒絶反応の治療. 腎移植・血管外科 1:25-31, 1989.

20) 落合武徳, 浅野武秀, 佐藤博, 柏木登, 深尾立・他:抗リンパ球血清の多施設におけるcontrolled studyの臨床結果. 移植 17:391-400, 1982.
Medical*Online

P.215 掲載の参考文献

1) Johannsen R, Seiler FR:The micro-complement fixation test as an assay of the immunosuppressive activty of anti-human lymphocyte globulin(AHLG). Behring Mitteilugen 51:33-39, 1972.

2) 早阪勇太郎, 高橋公太, 太田和夫:抗ヒトTリンパ球免疫グロブリン(ATG-F)の免疫学的な基礎検討. 今日の移植 6:415-421, 1993.

3) Arndt R, Hammerer P, Huland H, Kramer-Hansen H, Huland H:Treatment of acute cellular rejection in renal transplantation patients on ciclosporin with antithymocyte globulin. Urol. Int. 43:139-144, 1988.
pubmed

4) Andreas BH, Gallati H, Zurcher RM, Bachofen M, Mihatsch MJ et al.:A randomized prospective trial of prophylactic immunosuppression with ATG-F resdenius versus OKT 3 after renal transplantation. Transplantation 59:830-841, 1995.

5) Fassbinder W, Bechstein PB, Stutie HJ, Scheuermann EH, Hanke P et al.:Treatment of steroid-resistant rejections with ATG and/or plasma filtration improves graft survival after cadaveric kidney transplantation. Neth. J. Med. 28:265-267, 1985.
pubmed

6) 高橋公太, 石橋道夫, 打田和治, 安村忠樹, 八木澤隆・他:腎移植後の拒絶反応の治療に対するATG-Fの臨床評価(投稿中).

慢性拒絶反応の予防と治療

P.231 掲載の参考文献

1) Schweitzer EJ, Matas AJ, Gillingham KJ, Payne WD, Gores PF et al.:Causes of renal allograft loss. Ann. Surg. 214:688, 1991.

2) Cook DJ:Long term survival of kidney allografts, in Clinical Transplant 1987. (ed. TERAsAKI PI), Los Angeles, UCLA Tissue Typing Laboratory, 1987, p 277-285.

3) Maeda H, Sakamoto K, Matsushita K, Hachisu T, Yamada K et al.:Effect of hypertension, hyperlipidemia and cyclosporine therapy on long term renal allograft survival. Transplantation Proc. 28:1633-1634, 1996.

4) Cheigh JS, Stenzel KH, Sushin M, Rubin AL, Riggio RR et al.:Kidney transplant nephrotic syndrome. Am. J. Med. 57:730-740, 1974.

5) Paul LC, Hayri P, Foegh M, Dennis MJ, Mihatsch M et al.:Diagnostic criteria for chronic rejection/accelerated graft atherosclerosis in heart and kidney transplant:Proposal from the Fourth Alexis Carrel conference on chronic rejection and accelerated arteriosclerosis in transplanted organs. Transplant. Proc. 25:2020-2021, 1993.

6) Sanfilipo F:Renal transplantation. The pathology of organ transplantation. (ed. Sale GE), Butterworths, Boston, 1990, p 51-101.

7) Almond PS, Gillingham KJ, Silbley R et al.:Renal transplant function after ten years of cyclosporine. Transplantation 53:316-323, 1992.

8) Monga G, Mazzucco G, Messina M, Motta M, Quaranta S et al.:Intertubular capillary changes in kidney allografts:amorphologic investigation on 61 renal specimens. Mod. Pathol. 5:125-130, 1992.
pubmed

9) Mosmann TR, Cherwinski H, Bond MW, Giedllin MA, Coffman RL:Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J. Immunol. 136:2348-2358, 1986.

10) Street NE, Mosmann TR:Functional diversity of T lymphocytes due to secretion of different cytokine patterns. FASEB J. 5:171-177, 1991.
pubmed

11) Paul WE, Seder RA:Lymphocyte responses and cytokines. Cell 76:241-251, 1994.
pubmed

P.238 掲載の参考文献

1) Wang T, Donahoe PK, Zervos AS:Specific interaction of type I receptors of the TGF β family with the immunophilin FKBP 12. Science 265:674-676, 1994.

2) Ahuja S, Shrivastav S, Daielpour D, Balow J:Regulation of transforming growth factor-β and its receptor by cyclosporine in human T-lymphocytes. Transplantation 60:718-723, 1995.

3) Gjertson M, Cecka JM, Terasaki PI:The relative effects of FK 506and cyclosporine on short and long term kidney graft survival. Transplantation 60:1384-1388, 1995.

4) Morris RE:Rapamycins;antifungal, antitumor, antiproliferative and immunosuppressive macrolides. Transplant. Rev. 6:39-87, 1992.

5) 雨宮浩, 藤原大美, 山田研一:免疫抑制剤の分子生物学的作用機序に関する研究. 平成8年度厚生科学臓器技術臨床研究開発事業報告書 p11-14.

6) Brenner BM, Cohen RA, Milford EL:In renal transplantation, one size may not fit all. JASN 3:62-169, 1992.
pubmed

7) Dimeny E, Waiilberg J, Ltihell H, Fellstrom B:Hyperlipidemia in renal transplantation. Risk factor for long-term graft outcome, in Metabolic Factors and Outcome of Organ Transplantation. (ed. Dimeny E), Academic thesis, Uppsala University, Sweden, 1994.

8) Eich D, Thompson JA, Ko DJ, Hastillo A, Lower R et al.:Hypercholesterolemia in long-term survivors of heart transplantation:An early marker of accelerated coro- nary artery disease. J. Heart Lung. Transplant. 10:45-49, 1991.

9) Modena FM, Hostetter TH, Salahudeen AK, Najarian JS, Matas AJ et al.:Progression of kidney disease in chronic renal transplant rejection. Transplantation 52:239-244, 1994.

10) Brazy PC, Pirsch JD, Belzer FO:Factors affecting renal allograft function in Iong-term recipients. Am. J. Kidney Dis. 19:558-566, 1992.

11) Halloran PF, Aprile MA, Farewell V, Ludwin D, Smith ER et al.:Early function as the principal correlate of graft survival. Transplantation 46:223-228, 1988.

12) Yilmaz S, Paavonen T, Hayri P:Chronic rejection of rat renal allografts. II The impact of prolonged ischemia time on transplant histology. Transplantation 53:823-827, 1992.

13) 山田研一, 浜口欣一, 畠山恵美子, 坂本薫, 剣持敬, 前田博教, 松下一之, 柏原英彦, 横山健郎, 三浦靖彦, 中島一彰, 落合武徳:長期生着腎移植患者の心・血管系合併症による死の成因と病態. 移植 31:60-68, 1996.
Medical*Online

14) Ruef C, Dudde K, Lacy J, Northemann W, Bauman M et al.:Interleukin 6 is an autocrine growth factor for mesangial cells. Kidney Int. 38:249-257, 1990.

15) Paul LC, Solez K:Chronic rejection in vascularized organ allografts, in Organ Transplantation:Long-Term Results, (ed. Paul LC, Solez K), New York, Marcel Dekker Inc. 1992, p 99-134.

16) Russell PS, Chase CM, Winn HJ, Colvin RB:Coronary atherosclerosis in transplanted mouse hearts. III Effects of recipient treatment with a monoclonal antibody to interferon-γ. Transplantation 57:1367-1371, 1994.

17) Aziz S, Tada Y, Gordon D, McDonald TO, Fareed J et al.:A reduction in accelerated graft coronary disease and an improvement in cardiac allograft survival using low molecular weight heparin in combination with cyclosporine. J. Heart Lung Transplant. 12:634-643, 1993.

血漿交換療法

P.254 掲載の参考文献

1) 日本移植学会:腎移植臨床登録集計報告(1994. 中間報告). 移植 30:428-449, 1995.
Medical*Online

2) Hume DM, Meerrill JP, Miller BF, Geroge WT:Experiences with renal homotransplantation in the human:Report of nine cases. J. Clin. Invest. 34:327-333, 1955.

3) Starzl TE, Marchioro TL, Homes JH:Renal homografts in patients with major donor-recipient blood group incompatibilities. Surgery 55:195-200, 1964.

4) 太田和夫, 笹原鋼, 大坪修, 登政和:腎移植の臨床(1)-腎移植の適応とDonorの選択について-. 外科診療 11:862-867, 1969.

5) 園田孝夫, 栗田孝, 永野俊介:腎移植の臨床. 内科 20:703-708, 1967.

6) Slapak M, Naik RB, Lee HA:Renal transplant in a patient with major donor-recipient blood group incompatibility. Reversal of acute rejection by the use of modified plasmapheresis. Transplantation 31:4-7, 1981.

7) Alexandre GP, De Bruyere M, Squifflet JP, Moriau M, Latinne D et al.:Human ABO-incompatible living donor renal homografts. Nerth. J. Med. 28:231-234, 1985.

8) Cardella CJ:Plasma exchange and renal transplantation. J. Clin. Aphe. 2:405-409, 1985.

9) Bannett AD, Bensinger WI, Raja R, Baquero A, McAlack RF:Immunoadsorption and renal transplant in two patients with a major ABO incompatibility. Transplantation 43:909-911, 1987.
pubmed

10) 太田和夫, 高橋公太, 大場忍, 阿岸鉄三, 田辺一成・他:ABO不適合腎移植の一例. 腎と透析 27:117-121, 1989.

11) 名倉宏:腎の免疫系. ABO血液型不適合腎移植. (高橋公太編), 日本医学館, 東京, 1991, p17-23.

12) 藤井寿一:移植後の血液型酵素の生成. ABO血液型不適合腎移植. (高橋公太編), 日本医学館, 東京, 1991, p77-80.

13) 山崎雄一郎, 堀田茂, 山口裕, 高橋公太, 八木沢隆・他:ABO不適合腎移植の一例. -とくにABO型抗原の組織内分布について-. 腎移植・血管外科 2:152-156, 1990.

14) 太田和夫:ABO血液型不適合腎移植の意義. 腎と透析 30:167-169, 1991.

15) 清水勝:ABO式血液型とLewis式血液型. ABO血液型不適合腎移植. (高橋公太編), 日本医学館, 東京, 1991, p1-8.

16) 松前知治, 内藤説也, 荒川規矩男:膜型血漿交換療法. 日本臨床 1991年増刊:560-565, 1991.

17) 渋谷統寿, 藤下敏:血漿交換に伴う副作用. 日本臨床 1991年増刊:567-571, 1991.

18) 阿岸鉄三:置換補充液. 二重濾過血漿分離交換法. (阿岸鉄三編), 医学書院, 東京, 1984, p81-82.

19) 沼謙司, 小玉正智, 谷徹, 花沢一芳:血液吸着法概論. 日本臨床 1991年増刊:632-637, 1991.

20) 中島均:選択的血液型吸着剤Biosynsorb. ABO血液型不適合腎移植. (高橋公太編) 日本医学館, 東京, 1991, p25-28.

21) 阿岸鉄三, 高橋和夫, 大橋信子, 高橋公太, 八木沢隆・他:抗A抗体・抗B抗体の除去方法. 腎と透析 30:185-189, 1991.

22) Bensinger WI:Plasma exchange and immunoadsorption for removal of antibodies prior to ABO incompatible bone marrow transplant. Artficial Organs 5:254-258, 1981

23) 高橋公太, 阿岸鉄三, 大場忍, 田辺一成, 八木沢隆・他:ABO血液型不適合間生体腎移植13例の経験. 移植 26:95-104, 1991.
Medical*Online

P.269 掲載の参考文献

1) Ichikawa I, Fogo A:Focal segmental glomerlosclerosis. Pediatr. Nephrol. 10:374-391, 1996.
pubmed

2) Warady BA, Hebert D, Sullivan K, Alexander SR, Tejani A:Renal transplantation, chronic dialysis, and chronic renal insufficiency in children and adolescents. The 1995 Annual Report of the North American Pediatric Renal Transplantation Cooperative Study. Pediatr. Nephrol. 11:49-64, 1997.

3) 川口洋, 小松康宏, 服部元史, 大田敏之, 水島和一郎, 伊藤克己, 高橋公太, 田辺一成, 石川暢夫, 尊田和徳, 東間紘, 太田和夫:小児腎移植の成績. 今日の移植 10:331-336, 1997.

4) Pinto J, Jacerda G, Cameron JS, Turner DR, Bewick M, Ogg CS:Recurrence of focal segmental glomerulosclerosis in renal allografts. Transplantation 32:83-89, 1981.

5) Striegel JE, Siblex RK, Fryd DS, Mauer SM:Recurrence of focal segmeutal glomerulosclerosis in children following renal transplantation. Kidney Int. 30:S44-S50, 1986.

6) Mathew TII:Recurrence of disease following renal transplantation. Am. J. Kidney Dis. 12:85-96, 1988.

7) Sengguturan P, Cameron JS, Hartley RB et al.:Recurrence of focal segmental glomerulosclerosis in transplanted kidneys:analysis of incidence and risk factor in 59 alloglafts. Pediatr. Nephrol 4:21-28, 1990.

8) Dantal J, Baatard R, Hourmant M, Cantarovich D, Buzelin F, Soulillou Jp:Recurrent nephrotic syndrome following renal transplantation in patients with focal glomerulosclerosis. A one-center study of plasma exchange effects. Transplantation 52:827-831, 1991.
pubmed

9) Ingulli E, Tejani A:Incidence, treatment, and outcome of recurrent focal segmental glomerulosclerosis posttransplantation in 42 allografts in children-a single-center experience. Transplantation 5:401-405, 1991.
pubmed

10) Cameron JS:Recurrent primary disease and de novo nephritis following renal transplantation. Pediatr. Nephrol. 5:412-421, 1991.
pubmed

11) Artero M, Biava C, Amend W, Tomlanovich S, Vincenti F:Recurrent focal segmental glomerulosclerosis posttransplantation:natural history and response to therapy. Am. J. Med. 92:375-383, 1992.

12) Kim EM, Striegel J, Kim Y, Matas AJ, Najarian JS, Mauer SM:Recurrence of steroid-resistant nephrotic syndrome in kidney transplants is associated with in- creased acute renal failure and acute rejection. Kidney Int. 45:1440-1449, 1994.

13) 川口洋, 小松康宏, 服部元史, 長田道夫, 秋岡祐子, 水島和一郎, 伊藤克己, 高橋公太, 尊田和徳, 太田和夫:小児腎移植における再発性巣状糸球体硬化症(FSGS)について. 日本小児腎不全学会雑誌 15:34-36, 1995.

14) Kawaguchi H, Hattori M, Ito K, Takahashi K, Ota K:Recurrence of focal glomerulosclerosis of allografts in children:the efficacy of intensive plasma exchange therapy before and after renal transplantation. Transplant. Proc. 26:7-8, 1994.
pubmed

15) Rich AR:Ahithero undescribed vulnerability of the juxtamedullary glomeruli in lipoid nephrosis. Bull Johns Hoptinks Hosp. 100:173-186, 1957.
pubmed

16) Shinki H:Clinical and morphological predictors of renal outcome in adult patients with focal and segmental glomerulosclerosis(FSGS). Clin. Nephrol. 46:362-368, 1996.

17) Cameron JS:Recurrent primary disease and de novo nephritis following renal transplantation. (eds. Tejani AH, Fine RN), Pediatric Renal Transplantation, New York, Wiley-Liss, 1994, p503-523.

18) 川口洋, 服部元史, 伊藤克己, 高橋公太, 八木沢隆, 太田和夫:本邦における小児腎移植後の巣状糸球体硬化症(focal segmental glomerular sclerosis:FSGS)の再発について. 移植 27:60-67, 1992.

19) First MR:Living-related donor transplants should be performed with caution in patients with focal segmental glomerulosclerosis. Pediatr. Nephrol 9:S40-S42, 1995.
pubmed

20) Kershaw DB, Sedman AB, Kelsch RC, Bunchman TE:Recurrent focal segmental glomerulosclerosis in pediatric renal transplant recipients:successful treatment with oral cyclophosphamide. Clinical Transplantation 8:546-549, 1994.
pubmed

21) Zimmerman SW:Plasmapheresis and dipyridamole for recurrent focal glomerular sclerosis. Nephron 40:241-245, 1985.
pubmed

22) Savin VJ, Sharma R, Sharma M, McCarthy ET, Swan SK, Ellis E, Lovell H, Warady B, Gunwar S, Chonko AM, Artero M, Vincenti F:Circulating factor associated with increased glomerular permeability to albumin in recurrent focal segmental glomerulosclerosis. N. Eng. J. Med. 334:878-883, 1996.

23) Dantal J, Bigot E, Bogers W, Testa A, Kriaa F, Jacques Y, DeLigny BH, Niaudet P, Charpentier B, Soulillou Jp:Effect of protein adsorption on protein excretion in kidney-transplant recipients with recurrent nephrotic syndrome. N. Eng. J. Med. 330:7-14, 1994.

24) Cochat P, Kassir A, Colon S, Glastre C, Tourniaire B, Parchoux B, Martin X, David L:Recurrent nephrotic syndrome after transplantation:early treatment with plas- maphaeresis and cyclophosphamide. Pediatr. Nephrol. 7:50-54, 1993.

25) Savin VJ, Sharma R, Lovell HB, Welling DJ:Measurement of albumin reflection coefficient with isolated glomeruli. J. Am. Soc. Nephrol. 3:1260-1269, 1992.
pubmed

26) Mahan JD, Mauer M, Nevius TE:The Hicklnan catheter:anew hemodialysis access device for infants and small children. Kidney Int. 24:694-697, 1983.

27) Stephanian E, Matas AJ, Mauer M, Chavers B, Nevins T, Kashtan C, Sutherland DER, Gores P, Najarian JS:Recurrence of disease in patients retransplanted for focal segmental glomerulosclerosis. Transplantation 53:755-757, 1992.

28) Odorico JS, Knechtle SJ, Rayhill SC, Pirsch JD, D'Alessandro AM, Belzer FO, Sollinger HW:The influence of native nephrectomy on the incidence of recurrent disease following renal transplantation for primary glomerulonephritis. Transplantation 61:228-234, 1996.

はじめての方へ

個人／法人会員登録のご案内